Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

ANCA-Associated Vasculitis

Conditions

ANCA-Associated Vasculitis

Trial Timeline

Mar 15, 2017 → Nov 1, 2019

NCT ID

NCT02994927

About Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine

Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine is a phase 3 stage product being developed by Amgen for ANCA-Associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02994927. Target conditions include ANCA-Associated Vasculitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02994927	Phase 3	Completed	Mar 15, 2017	Nov 1, 2019	ANCA-Associated Vasculitis

Competing Products

3 competing products in ANCA-Associated Vasculitis

See all competitors

Product	Company	Stage	Hype Score
rituximab + Placebo	Roche	Phase 3	77
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids	Amgen	Phase 2	51
Abatacept (Orencia)	Bristol Myers Squibb	Phase 2	51

Other Products from Amgen